IP Library Granted Patent US 9,260,428
Granted Patent B2
US 9,260,428 · App. 14/039,367 · Granted Feb 16, 2016

Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds

Inventors: Ingrid Mergelsberg (Mahwah, NJ); Dominik Hermann Scherer (Horw, CH); Monika Erika Huttenloch (Kriens, CH); Hon-Chung Tsui (East Brunswick, NJ); Sunil Paliwal (Monroe Township, NJ); Neng-Yang Shih (Lexington, MA)
Assignee: OPKO Health, Inc.
C07D471/10C07D211/38C07D211/56C07D498/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,260,428
App. No.
14/039,367
Filed
Sep 27, 2013
Granted
Feb 16, 2016
Kind
B2
Art Unit
1626
USPC
546/16
Abstract

This application discloses a process to synthesize 8-({1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-pheny-1.7-diaza-spiro[4.5]decan-2-one comprising reacting a compound of the Formula 27a-sulfonate with zinc in the presence of acetic acid.

Claims (28)

1. A process for making compounds of Formula I

the process comprising:

(a) reacting the protected enamine of Formula III, wherein R 2 is an enamine protecting group removable by catalytic hydrogenation,

with a nitrating agent to form the corresponding protected nitro-enamine of Formula and subsequently reducing the product to a protected piperidine of Formula IV, wherein R 2 is as defined above;

(b) deprotecting the protected piperidine of Formula IV from step “a” by reacting it with hydrogen in the presence of a palladium catalyst to form the compound of Formula V,

(c) alkylating the compound of Formula V by reacting it under Michael addition conditions with an acrylate of the formula 28a,

to form the compounds of Formulae 27a and 27b,

(c) precipitating a sulfonate salt of Formula 27a-sulfonate by reacting the compounds of Formula 27a and 27b formed in Step “c” with a sulfonic acid of the formula R 5 —SO 3 H,

 and

(d) forming the lactam of Formula I by treating the compound of Formula 27a-sulfonate with acetic acid in the presence of zinc metal;

wherein R 5 is selected from benzyl, p-tolyl, and methyl and R 1 is a linear, branched, or cyclic alkyl having up to 6 carbon atoms, phenyl, 2-methoxy-ethyl, 2-(dimethylamino)ethyl, (L)-menthyl, (D)-Menthyl, Dimethylamide, (R)-Benzyl -oxazolidinonamide, (S)-benzyl-oxazolidinonamide, isobornyl, cis-pinan-2-yl, isopinocamphenyl, adamantylmethyl, 2-adamantyl, 1-adamantyl, and (−)-8-phenylmenthyl.

2. The process of claim 1 wherein R 1 is selected from methyl, (−)-8-phenylmenthyl, isobornyl, 1-adamantyl, 2-adamantyl, adamantylmethyl, and (+)-isopinocamphenyl.

3. The process of claim 1 , wherein R 2 is Cbz.

4. The process of claim 3 , wherein R 1 is methyl.

5. A composition comprising the mixture of the compounds of Formula I and Formula Ia1

6. A process for preparing the compound of Formula I from the compound of Formula Ia1,

the process comprising reducing the compound of Formula Ia1 with hydrogen in the presence of Raney Nickel.

7. A compound of the formula:

wherein

R 1 is cyclic alkyl having up to 6 carbon atoms, phenyl, 2-methoxy-ethyl, 2 (dimethylamino)ethyl, (L)-menthyl, (D)-menthyl, dimethylamide, (R) benzyl-oxazolidinonamide, (S)-benzyl-oxazolidinonamide, isobornyl, cis-pinan-2-yl, isopinocampheyl, adamantylmethyl, 2-adamantyl, 1-adamantyl, or (−)-8 phenylmenthyl;

or

wherein:

R 1 is linear, branched or cyclic alkyl having up to 6 carbon atoms, phenyl, 2-methoxy-ethyl, 2-(dimethylamino)ethyl, (L)-menthyl, (D)-menthyl, dimethylamide, (R)-benzyl-oxazolidinonamide, (S)-benzyl-oxazolidinonamide, isobornyl, cis-pinan-2-yl, isopinocampheyl, adamantylmethyl, 2-adamantyl, 1-adamantyl, and (−)-8-phenylmenthyl; and

R 5 is selected from alkyl, benzyl, and p-tolyl.

8. The compound of claim 7 , wherein said compound is a compound of

wherein R 5 is methyl.

9. The process of claim 1 , further comprising:

(e) precipitating an hydrochloride salt form of the compound of Formula I by reacting the free-base compound of Formula I with HCl.

Assignments (6)
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENTS AT R/F 41939/0487, 46591/0544 AND 53940/0001 Recorded Apr 15, 2026
From: MIDCAP FINANCIAL TRUST
To: TERSERA THERAPEUTICS LLC,
Reel/Frame 075420/0453 →
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2023
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: TERSERA THERAPEUTICS LLC
Reel/Frame 063253/0942 →
FIRST LIEN PATENT SECURITY AGREEMENT Recorded Jul 19, 2018
From: TERSERA THERAPEUTICS LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 046591/0544 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR EXECUTION DATE PREVIOUSLY RECORDED AT REEL: 036348 FRAME: 0212. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 7, 2016
From: SCHERING CORPORATION
To: OPKO HEALTH, INC.
Reel/Frame 037459/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: MERGELSBERG, INGRID; SCHERER, DOMINIK HERMANN; HUTTENLOCH, MONIKA ERIKA; TSUI, HON-CHUNG; PALIWAL, SUNIL; SHIH, NENG-YANG
To: SCHERING CORPORATION
Reel/Frame 036348/0158 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: SCHERING CORPORATION
To: OPKO HEALTH, INC.
Reel/Frame 036348/0212 →
Continuity (3)
Division 12531859
Provisional Application 60919666 · Mar 22, 2007
Related Publication 20140024834A1 · Jan 23, 2014